FDA's "Import For Export" Proposed Rule Criticized By HIMA, Abbott Labs
This article was originally published in The Gray Sheet
Executive Summary
FDA's interpretation of the term "component" in its "Import for Export" proposed rule is too broad and needs to be narrowed, the Health Industry Manufacturers Association and Abbott Laboratories contend in separate but similarly worded comments recently submitted to the agency.